Ken Fisher’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-662,504
Closed -$32.3M 1057
2025
Q3
$32.3M Sell
662,504
-26,638
-4% -$1.65M 0.01% 272
2025
Q2
$51.4M Sell
689,142
-45,401
-6% -$3.01M 0.02% 214
2025
Q1
$46.7M Buy
734,543
+22,769
+3% +$1.55M 0.02% 219
2024
Q4
$55.6M Buy
711,774
+22,265
+3% +$1.79M 0.02% 213
2024
Q3
$55.4M Sell
689,509
-3,545
-0.5% -$286K 0.02% 212
2024
Q2
$57.3M Sell
693,054
-4,986
-0.7% -$439K 0.02% 207
2024
Q1
$59.6M Sell
698,040
-13,627
-2% -$1.07M 0.03% 203
2023
Q4
$60.9M Sell
711,667
-150,953
-17% -$13.1M 0.03% 197
2023
Q3
$77.3M Sell
862,620
-40,124
-4% -$3.58M 0.04% 205
2023
Q2
$76.9M Buy
902,744
+3,916
+0.4% +$331K 0.04% 216
2023
Q1
$74.4M Sell
898,828
-207,869
-19% -$16.8M 0.05% 217
2022
Q4
$87M Sell
1,106,697
-140,846
-11% -$11.3M 0.06% 190
2022
Q3
$92.4M Sell
1,247,543
-22,231
-2% -$1.6M 0.07% 179
2022
Q2
$82.8M Buy
1,269,774
+81,616
+7% +$4.83M 0.06% 164
2022
Q1
$75.1M Sell
1,188,158
-6,487
-0.5% -$353K 0.04% 201
2021
Q4
$63.4M Buy
1,194,645
+91,752
+8% +$5.59M 0.04% 225
2021
Q3
$77.9M Buy
1,102,893
+4,160
+0.4% +$263K 0.05% 195
2021
Q2
$73.2M Buy
1,098,733
+946,106
+620% +$66.9M 0.05% 205
2021
Q1
$16.9M Sell
152,627
-1,507
-1% -$186K 0.01% 321
2020
Q4
$18.3M Sell
154,134
-580
-0.4% -$62.4K 0.01% 310
2020
Q3
$13.5M Sell
154,714
-14,207
-8% -$1.24M 0.01% 312
2020
Q2
$15.1M Sell
168,921
-7,926
-4% -$801K 0.01% 303
2020
Q1
$17.6M Sell
176,847
-12,124
-6% -$1.31M 0.02% 252
2019
Q4
$21.7M Sell
188,971
-48,817
-21% -$5.91M 0.02% 271
2019
Q3
$30M Buy
237,788
+2,482
+1% +$315K 0.03% 243
2019
Q2
$28.3M Sell
235,306
-36,273
-13% -$3.57M 0.03% 262
2019
Q1
$23.8M Buy
271,579
+28,855
+12% +$2.62M 0.03% 276
2018
Q4
$24.3M Buy
242,724
+114,078
+89% +$12M 0.03% 257
2018
Q3
$14.7M Sell
128,646
-77,118
-37% -$7.98M 0.02% 310
2018
Q2
$18.5M Sell
205,764
-13,347
-6% -$1.13M 0.02% 292
2018
Q1
$16M Sell
219,111
-6,528
-3% -$448K 0.02% 299
2017
Q4
$13.1M Sell
225,639
-17,636
-7% -$929K 0.02% 319
2017
Q3
$10.9M Buy
243,275
+1,728
+0.7% +$71.8K 0.02% 319
2017
Q2
$9.54M Sell
241,547
-420
-0.2% -$17.3K 0.01% 327
2017
Q1
$9.82M Sell
241,967
-25,700
-10% -$1M 0.02% 301
2016
Q4
$10.8M Sell
267,667
-45
-0% -$1.7K 0.02% 292
2016
Q3
$9.69M Buy
267,712
+10,245
+4% +$352K 0.02% 298
2016
Q2
$7.83M Buy
257,467
+38,340
+17% +$1.16M 0.01% 309
2016
Q1
$7.49M Buy
219,127
+17
+0% +$549 0.01% 314
2015
Q4
$7.06M Buy
219,110
+10,190
+5% +$331K 0.01% 326
2015
Q3
$6.75M Buy
208,920
+19,400
+10% +$730K 0.01% 315
2015
Q2
$7.84M Sell
189,520
-4,725
-2% -$199K 0.02% 304
2015
Q1
$8.72M Hold
194,245
0.02% 298
2014
Q4
$7.27M Buy
194,245
+16,600
+9% +$608K 0.02% 311
2014
Q3
$6.2M Hold
177,645
0.01% 310
2014
Q2
$6.27M Buy
177,645
+30,200
+20% +$1.01M 0.01% 311
2014
Q1
$4.8M Sell
147,445
-550
-0.4% -$21K 0.01% 320
2013
Q4
$6.24M Sell
147,995
-21,250
-13% -$874K 0.01% 297
2013
Q3
$6.75M Hold
169,245
0.02% 289
2013
Q2
$7M Buy
+169,245
New +$6.85M 0.02% 275

Other funds holding HAE

Ken Fisher's HAE Position: Q4 2025 in Review

Ken Fisher sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 662,504 shares — an estimated $32.3M sold.

Ken Fisher first reported a position in HAE in Q2 2013 and held it in 50 quarters. The position peaked at $92.4M in Q3 2022. 328 funds tracked by Wall St. Rank hold HAE as of Q4 2025.

  • Ken Fisher reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
  • Ken Fisher sold 662,504 Haemonetics shares in Q4 2025, an estimated $32.3M.
  • Ken Fisher first reported a position in Haemonetics in Q2 2013 and held it in 50 quarters.
  • Ken Fisher's Haemonetics position peaked at $92.4M in Q3 2022.
  • 328 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.

Based on Fisher Asset Management's 13F filing for Q4 2025, filed 9 Feb 2026.